AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7337944 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-treated group (DMP + MPS)
Number of subjects: 172
Study 31755948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin therapy for at least 14 days within 90 days of diagnosis
Number of subjects: 6174
Study 31755948 — intervention group
Group type: COMPARATOR
Intervention: No rifampin therapy
Number of subjects: 6174
Study 28774794 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 20 minutes
Number of subjects: 9
Study 26477692 — intervention group
Group type: EXPERIMENTAL
Intervention: ETABJ (matched etanercept and 50 ml blueberry juice daily)
Number of subjects: 201
Study 26477692 — intervention group
Group type: COMPARATOR
Intervention: ETAPJ (matched etanercept and placebo juice)
Number of subjects: 201
Study 26477692 — intervention group
Group type: COMPARATOR
Intervention: ETA (50 mg of etanercept twice weekly)
Number of subjects: 201
Study 23566183 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (details not specified)
Number of subjects: 22
Study 23566183 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 22
Study 21698987 — intervention group
Group type: EXPERIMENTAL
Intervention: DenShield desensitizing system (in-office application of DenShield Starter paste and at-home use of DenShield dentifrices for 6 months)
Number of subjects: 31
Study 21698987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 31
Study 19705205 — intervention group
Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 716
Study 17189962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus venlafaxine
Number of subjects: 116
Study 17189962 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch plus placebo
Number of subjects: 116
Study 15371578 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a monotherapy (180 microg once weekly)
Number of subjects: 537
Study 15371578 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus lamivudine (100 mg daily)
Number of subjects: 537
Study 15371578 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg daily)
Number of subjects: 537
Study 11773925 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina clinic (optimized antianginal medications)
Number of subjects: 535
Study 11773925 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 535
Study 9842823 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 microg/kg 90 min before spinal anesthesia
Number of subjects: 48
Study 9842823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 48
Study 8080740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact A5B7 IgG1 mouse monoclonal antibody (MAb) to CEA
Number of subjects: 19
Study 8080740 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2 fragment of the same antibody
Number of subjects: 19
Study 8080740 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 19
Study 2757960 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 660
Study 2757960 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage C treatment
Number of subjects: 660
Study 2757960 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and response to treatment
Number of subjects: 660
Study 2757960 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 660
Study 2757960 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of death analysis
Number of subjects: 660
Study 862429 — intervention group
Group type: EXPERIMENTAL
Intervention: Synemol cream (0.025%)
Number of subjects: 0
Study 862429 — intervention group
Group type: COMPARATOR
Intervention: Diproson cream (0.05%)
Number of subjects: 0
Study 862429 — intervention group
Group type: COMPARATOR
Intervention: Aristocort‐A cream (0.5%)
Number of subjects: 0
Study 862429 — intervention group
Group type: COMPARATOR
Intervention: Valisone cream (0.1%)
Number of subjects: 0
Study 31675420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Contraceptive Vaginal Rings (CCVR)
Number of subjects: 130
Study 31675420 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from COCP to CCVR
Number of subjects: 130
Study 31675420 — intervention group
Group type: COMPARATOR
Intervention: Crossover from CCVR to COCPs or NET-EN
Number of subjects: 130
Study 31675420 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone Oenanthate (NET-EN)
Number of subjects: 130
Study 31675420 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptive Pills (COCPs)
Number of subjects: 130
Study 30992659 — intervention group
Group type: EXPERIMENTAL
Intervention: KM-819 (FAS-associated factor 1 inhibitor)
Number of subjects: 0
Study 27755057 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB) of 10 mL of bupivacaine 0.0625% with fentanyl 2 μg/mL
Number of subjects: 40
Study 27755057 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB with varying intervals (30, 40, 50, 60 minutes)
Number of subjects: 40
Study 26102447 — intervention group
Group type: EXPERIMENTAL
Intervention: HITIDES intervention (collaborative care for depression)
Number of subjects: 249
Study 26102447 — intervention group
Group type: COMPARATOR
Intervention: Usual care (enhanced usual care)
Number of subjects: 249
Study 23800977 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril 10 mg/day
Number of subjects: 120
Study 23800977 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg/day
Number of subjects: 120
Study 23800977 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 100 mg/day
Number of subjects: 120
Study 23800977 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 120
Study 21711255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment from day 1 without detoxification
Number of subjects: 61
Study 21711255 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient detoxification program without preventive treatment from day 1
Number of subjects: 61
Study 21711255 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 61
Study 21711255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment
Number of subjects: 61
Study 18353314 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg reteplase in 300 mL Ringer's lactate
Number of subjects: 26
Study 18353314 — intervention group
Group type: COMPARATOR
Intervention: 300 mL Ringer's lactate only
Number of subjects: 26
Study 18353314 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 26
Study 16442897 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion during primary PCI
Number of subjects: 81
Study 16442897 — intervention group
Group type: COMPARATOR
Intervention: Non-GIK group (control)
Number of subjects: 81
Study 16442897 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of GIK vs Non-GIK
Number of subjects: 81
Study 15803238 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum combined with intraperitoneal saline washout (LPSW)
Number of subjects: 124
Study 15803238 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure pneumoperitoneum (LP)
Number of subjects: 124
Study 11331141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 24
Study 11331141 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 24
Study 11331141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9204744 — intervention group
Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 60
Study 9204744 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CC)
Number of subjects: 60
Study 8490078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 4 weeks
Number of subjects: 0
Study 8490078 — intervention group
Group type: COMPARATOR
Intervention: Placebo, H2-antagonists, or omeprazole
Number of subjects: 0
Study 3130687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine treatment
Number of subjects: 40
Study 3130687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29344879 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 184
Study 29344879 — intervention group
Group type: COMPARATOR
Intervention: Placebo 100 mg/day
Number of subjects: 184
Study 27956407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 12 weeks
Number of subjects: 55
Study 27956407 — intervention group
Group type: COMPARATOR
Intervention: LMCA segments with HRM
Number of subjects: 55
Study 24277055 — intervention group
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (IPC)
Number of subjects: 19
Study 24277055 — intervention group
Group type: COMPARATOR
Intervention: sham intermittent forearm ischemia (control)
Number of subjects: 19
Study 23880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-vaginal sampling
Number of subjects: 2000
Study 23880151 — intervention group
Group type: COMPARATOR
Intervention: Health professional-guided cervical sampling
Number of subjects: 2000
Study 23880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cytology classified as normal
Number of subjects: 2000
Study 23880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological samples classified as ASC-US+
Number of subjects: 2000
Study 23880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological samples classified as LSIL
Number of subjects: 2000
Study 23880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological samples classified as HSIL
Number of subjects: 2000
Study 19590947 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief and intensive behavioral interventions
Number of subjects: 1483
Study 17258218 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 60
Study 17258218 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 17258218 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 60
Study 17043834 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% urea lacquer applied once daily for 28 days
Number of subjects: 60
Study 17043834 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% urea lacquer applied twice daily for 28 days
Number of subjects: 60
Study 17043834 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (other hand)
Number of subjects: 60
Study 12393429 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment with fludarabine and rituximab
Number of subjects: 104
Study 12393429 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with fludarabine followed by rituximab
Number of subjects: 104
Study 12160584 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration plus Anandron
Number of subjects: 399
Study 12160584 — intervention group
Group type: COMPARATOR
Intervention: Surgical castration
Number of subjects: 399
Study 10513457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fananserin (600 mg/day) with slow titration (100 mg increases every 3 days)
Number of subjects: 26
Study 10513457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fananserin (600 mg/day) with rapid titration (200 mg increases every 3 days)
Number of subjects: 26
Study 10513457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fananserin (600 mg/day) with intermediate titration (100 mg increases every 2 days)
Number of subjects: 26
Study 10513457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fananserin (multiple doses)
Number of subjects: 26
Study 8055896 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training at 4.19 rad.s‐1 (n = 13)
Number of subjects: 23
Study 8055896 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training at 1.05 rad.s‐1 (n = 10)
Number of subjects: 23
Study 8055896 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) performing no training
Number of subjects: 23
Study 2898027 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine resin (12 g, twice a day)
Number of subjects: 264
Study 2898027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg, twice a day)
Number of subjects: 264
Study 2898027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg, twice a day)
Number of subjects: 264
Study 30060902 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (CLA): clarithromycin 500mg, lansoprazole 30mg, amoxicillin 1g, all bid for 10 days
Number of subjects: 227
Study 30060902 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-based therapy (PLA): pantoprazole 80mg, levofloxacin 500mg, azithromycin 500mg, all od for 10 days
Number of subjects: 227
Study 28588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection (triamcinolone acetate)
Number of subjects: 80
Study 28588166 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 80
Study 25577713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.3 mL per side, intranasally)
Number of subjects: 87
Study 25577713 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (0.3 mL per side, intranasally)
Number of subjects: 87
Study 23828709 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cesarean hysterectomy by peritoneum lateral approach
Number of subjects: 8
Study 23828709 — intervention group
Group type: COMPARATOR
Intervention: Conventional cesarean hysterectomy
Number of subjects: 8
Study 21967156 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 21967156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21298859 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 17802
Study 21298859 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 17802
Study 17116021 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-333369 (100-750 mg)
Number of subjects: 52
Study 17116021 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-333369 (750 mg)
Number of subjects: 52
Study 17116021 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-333369 (750 mg) under fed conditions
Number of subjects: 52
Study 17116021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15592291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 59
Study 15592291 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous terbutaline
Number of subjects: 59
Study 11451268 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic pacing (AAI or DDD)
Number of subjects: 0
Study 11451268 — intervention group
Group type: COMPARATOR
Intervention: Ventricular-based pacing
Number of subjects: 0
Study 9209786 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) 400 mg/day, orally
Number of subjects: 49
Study 9209786 — intervention group
Group type: COMPARATOR
Intervention: No treatment (non-CAM)
Number of subjects: 49
Study 9209786 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM)
Number of subjects: 49
Study 7957544 — intervention group
Group type: EXPERIMENTAL
Intervention: Umespirone 20 mg
Number of subjects: 44
Study 7957544 — intervention group
Group type: EXPERIMENTAL
Intervention: Umespirone 80 mg
Number of subjects: 44
Study 7957544 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 44
Study 7957544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3624110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg single oral dose)
Number of subjects: 84
Study 3624110 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (2 g single oral dose and 500 mg four times per day for five days)
Number of subjects: 84
Study 31909431 — intervention group
Group type: COMPARATOR
Intervention: Off-OAC group (3149 patients)
Number of subjects: 4512
Study 31909431 — intervention group
Group type: EXPERIMENTAL
Intervention: On-OAC group (1363 patients)
Number of subjects: 4512
Study 31909431 — intervention group
Group type: COMPARATOR
Intervention: OAC discontinuation
Number of subjects: 4512
Study 31909431 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of ischaemic stroke/transient ischaemic attack/systemic embolism
Number of subjects: 4512
Study 31909431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 4512
Study 31172934 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-spatial training
Number of subjects: 30
Study 31172934 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurorehabilitation (Control)
Number of subjects: 30
Study 28872081 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso+SBP group
Number of subjects: 0
Study 28872081 — intervention group
Group type: COMPARATOR
Intervention: Iso group
Number of subjects: 0
Study 26685401 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserving the great auricular nerve
Number of subjects: 81
Study 26685401 — intervention group
Group type: COMPARATOR
Intervention: No preserving the great auricular nerve
Number of subjects: 81
Study 23328881 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide intervention including education on smoking hazards and ETS exposure, conducted by trained professionals.
Number of subjects: 0
Study 23328881 — intervention group
Group type: COMPARATOR
Intervention: Control group (villages not receiving the intervention).
Number of subjects: 0
Study 21782948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial-dose doxycycline (SDD) for 3 months
Number of subjects: 45
Study 21782948 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial-dose doxycycline (ADD) for 2 weeks
Number of subjects: 45
Study 21782948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19812587 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 48
Study 19812587 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 48
Study 16469161 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 0
Study 16469161 — intervention group
Group type: COMPARATOR
Intervention: saccharin
Number of subjects: 0
Study 15131558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rosiglitazone for 6 months
Number of subjects: 16
Study 15131558 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 16
Study 15131558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rosiglitazone
Number of subjects: 16
Study 15131558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11296803 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercises (SE) and continuous passive motion (CPM)
Number of subjects: 120
Study 11296803 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercises (SE) and slider board (SB) therapy
Number of subjects: 120
Study 11296803 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercises (SE) alone
Number of subjects: 120
Study 9310811 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnoea tests without CO2 augmentation (group A)
Number of subjects: 55
Study 9310811 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnoea tests with CO2 augmentation (group B)
Number of subjects: 55
Study 8317029 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (priming dose i.m. at wound closure, sublingual buprenorphine every eight hours)
Number of subjects: 3
Study 8317029 — intervention group
Group type: COMPARATOR
Intervention: Morphine (priming dose i.m. at wound closure, sublingual placebo every eight hours)
Number of subjects: 3
Study 2873106 — intervention group
Group type: EXPERIMENTAL
Intervention: Extempore combination of salbutamol syrup plus 30‐mg oxatomide tablets
Number of subjects: 40
Study 2873106 — intervention group
Group type: COMPARATOR
Intervention: 30‐mg oxatomide tablets alone
Number of subjects: 40
Study 31511891 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery in rHEMI+ patients
Number of subjects: 195
Study 31511891 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment in rHEMI+ patients
Number of subjects: 195
Study 31511891 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery in rHEMI- patients
Number of subjects: 195
Study 31511891 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment in rHEMI- patients
Number of subjects: 195
Study 31511891 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment for rHEMI+ vs rHEMI- patients
Number of subjects: 195
Study 29447309 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized zirconia abutments (AC)
Number of subjects: 28
Study 29447309 — intervention group
Group type: COMPARATOR
Intervention: Customized titanium abutments (MC)
Number of subjects: 28
Study 26954991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise alone
Number of subjects: 14
Study 26954991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and cognitive training combined
Number of subjects: 14
Study 26549374 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding stents
Number of subjects: 69
Study 26549374 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable stents
Number of subjects: 69
Study 23701262 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 5 mg BID
Number of subjects: 39
Study 23701262 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 10 mg QD
Number of subjects: 39
Study 23701262 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 25 mg BID
Number of subjects: 39
Study 23701262 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK256073 50 mg QD
Number of subjects: 39
Study 23701262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 20496734 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 86
Study 20496734 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 86
Study 17454835 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate drink
Number of subjects: 18